Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years-Reference-Cited by-同舟云学术

Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years

Published:2022-08-01 Issue:6 Volume:18 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Yin J. Kevin¹²,Pepin Stephanie³,van Aalst Robertus⁴⁵⁶,Loiacono Matthew M.⁷,Samson Sandrine I.⁸

Affiliation:

1. Global Medical Affairs, Sanofi, Singapore

2. Faculty of Medicine and Health, The University of Sydney, NSW, Australia

3. Global Clinical Sciences, Sanofi, Lyon, France

4. Department of Modeling, Epidemiology and Data Science, Global Medical Affairs, Sanofi, Lyon, France

5. Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA

6. Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

7. Global Medical Evidence Generation, Sanofi, Swiftwater, PA, USA

8. Global Medical Affairs, Sanofi, Lyon, France

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2022.2106749

Reference12 articles.

1. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis

2. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial

3. Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”

4. Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

5. The U.S. Centers for Disease Control and Prevention (CDC). Vaccine effectiveness: how well do flu vaccines work? 2021. https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply letter to “Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal”;Journal of Medical Economics;2023-07-24